ORAL MUCOSITIS INDUCED BY RADIATION/CHEMOTHERAPY; CHALLENGES IN THERAPEUTIC IMPLICATIONS AND FUTURE PROSPECTS
Authors:
- Pradeep Js JsPJPradeep Js Js
- Jey Kumar PachiyappanJPJey Kumar Pachiyappan
- Jagan SenthilkumarJSJagan Senthilkumar
- Roshan Tej SekarRSRoshan Tej Sekar
- Kousalya SelvarajKSKousalya Selvaraj
Open Access
- 7 March 2025
- journal article
- Published by Innovare Academic Sciences Pvt Ltd in Asian Journal of Pharmaceutical and Clinical Research
- p. 1-9
Abstract
Oral mucositis (OM) is a common and debilitating side effect of cancer treatments, primarily chemotherapy and radiotherapy. Inflammation of the oral mucosa leads to various severe outcomes, which affect the quality of life in patients. Sometimes, inhibition of treatment may be necessary, which may lead to insubstantial evasion of cancer therapy. The review article discusses current prevention and management techniques, such as oral hygiene protocols, cryotherapy, low-level laser therapy, and pharmacological interventions, including palifermin. It also comments on the risk factors that include the type of cancer, treatment protocols, and patient-related factors. It finally speaks about the clinical and economic impact of OM in the treatment of cancer and healthcare systems.Keywords
This publication has 26 references indexed in Scilit:
- In Reply to Li et alInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2021
- Declining Medical Student Interest in Radiation Oncology: Wake-Up Call With a Silver Lining?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2021
- Resource-sparing curative-intent hypofractionated-accelerated radiotherapy in head and neck cancer: More relevant than ever before in the COVID eraOral Oncology, 2020
- Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinomaCancer, 2020
- MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapyCancer, 2020
- Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trialThe Lancet Oncology, 2020
- Rapidly expanding mixed lesion of the maxilla in a 17-month-old boyOral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2018
- Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statements.Critical Reviews in Oncology/Hematology, 2016
- Chemotherapy or Radiation-Induced Oral MucositisDental Clinics of North America, 2014
- The pathobiology of mucositisNature Reviews Cancer, 2004